Vimarsana
Biggest News Aggregation in the World

Page 28 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nuclear Export Today - Breaking & Trending Today

Menarini Industrie Farmaceutiche Riunite: Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma - Vimarsana News

Menarini Industrie Farmaceutiche Riunite: Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

Published: May 20, 2022

-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy, May 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI),

Source: finanznachrichten.de
Related Topics:
United StatesUnited KingdomNorthern IrelandRichard PaulsonElcin Barker ErgunSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncMenarini GroupDrug AdministrationEuropean CommissionWorld Health OrganizationPrnewswire Karyopharm Therapeutics IncExchange CommissionEuropean UnionEuropean Medicines AgencyEuropean Commission DecisionCommittee For Medicinal Products Human UseCommission Decision AnticipatedMedicinal ProductsHuman UseChief Executive OfficerPivotal PhaseIndependent Review CommitteeVery Good Partial ResponseMultiple Myeloma
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress - Vimarsana News

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress

Published: May 12, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomKyongsang BuktoSouth KoreaHaris AliReshma RangwalaSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncAmerican Society Of Clinical OncologyDrug AdministrationEuropean Hematology AssociationPrnewswire Karyopharm Therapeutics IncExchange CommissionKaryopharm Selective Inhibitor Of Nuclear ExportInformation DepartmentAmerican SocietyClinical OncologyAnnual MeetingChief Medical OfficerSelective InhibitorNuclear ExportMedical InformationFetal ToxicityKaryopharm TherapeuticsPrivate Securities Litigation Reform Act
Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress - Vimarsana News

Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

Published: May 5, 2022

– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – –...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomKyongsang BuktoSouth KoreaRichard PaulsonReshma RangwalaMichael KauffmanSharon ShachamSelective Inhibitor Of Nuclear ExportAmerican Society Of Clinical OncologyEuropean Society Of Medical Oncology Virtual PlenaryKaryopharm Selective Inhibitor Of Nuclear ExportMenarini GroupPromedico LtdCommittee For Medicinal Products Human UseInformation DepartmentKaryopharm Therapeutics IncSociety For Gynecologic OncologyDrug AdministrationEuropean CommissionPrnewswire Karyopharm Therapeutics IncExchange CommissionHealthcare Royalty ManagementAntengene TherapeuticsAchieved First Quarter
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published: May 2, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United KingdomReshma RangwalaSelective Inhibitor Of Nuclear ExportPrnewswire Karyopharm Therapeutics IncKaryopharm Therapeutics IncCompensation CommitteeExecutive Vice PresidentChief Medical OfficerStock IncentiveStock Incentive PlanNasdaq Listing RuleSelective InhibitorNuclear ExportKaryopharm TherapeuticsKaryopharm Therapeutics Inc
Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022 - Vimarsana News

Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022

Published: April 28, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...

Source: prnewswire.com
Related Topics:
United KingdomSelective Inhibitor Of Nuclear ExportPrnewswire Karyopharm Therapeutics IncKaryopharm Therapeutics IncCall ScheduledKaryopharm TherapeuticsSelective InhibitorNuclear ExportKaryopharm Therapeutics Inc